ID: ALA3086850

Max Phase: Preclinical

Molecular Formula: C157H240N40O46

Molecular Weight: 3423.88

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CC(C)[C@H](NC(=O)C(NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](C)NC(=O)C(NC(=O)[C@H](Cc1ccccc1)NC(=O)C(NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)C(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)C(NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(C)(C)C(=O)O)[C@@H](C)O)C(C)(C)C)C(C)C)C(C)(C)C)C(C)(C)C(=O)O)C(C)(C)C)C(C)(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)(C)C(=O)O

Standard InChI:  InChI=1S/C157H240N40O46/c1-75(2)109(189-129(220)100(66-108(208)209)182-135(226)103(73-200)187-143(234)114(153(16,17)18)193-131(222)97(61-82-41-30-28-31-42-82)183-139(230)111(81(9)201)188-106(205)70-169-140(231)116(155(22,23)147(238)239)195-123(214)80(8)172-124(215)89(160)65-86-68-165-74-170-86)138(229)186-102(72-199)136(227)185-101(71-198)134(225)181-96(63-84-50-52-87(202)53-51-84)130(221)192-113(152(13,14)15)142(233)179-94(55-57-107(206)207)125(216)168-69-105(204)175-95(54-56-104(161)203)126(217)173-77(5)120(211)171-78(6)121(212)177-92(47-36-38-58-158)127(218)197-118(157(26,27)149(242)243)146(237)184-98(62-83-43-32-29-33-44-83)132(223)191-112(151(10,11)12)141(232)174-79(7)122(213)180-99(64-85-67-167-90-46-35-34-45-88(85)90)133(224)194-115(154(19,20)21)144(235)190-110(76(3)4)137(228)178-93(48-37-39-59-159)128(219)196-117(156(24,25)148(240)241)145(236)176-91(119(162)210)49-40-60-166-150(163)164/h28-35,41-46,50-53,67-68,74-81,89,91-103,109-118,167,198-202H,36-40,47-49,54-66,69-73,158-160H2,1-27H3,(H2,161,203)(H2,162,210)(H,165,170)(H,168,216)(H,169,231)(H,171,211)(H,172,215)(H,173,217)(H,174,232)(H,175,204)(H,176,236)(H,177,212)(H,178,228)(H,179,233)(H,180,213)(H,181,225)(H,182,226)(H,183,230)(H,184,237)(H,185,227)(H,186,229)(H,187,234)(H,188,205)(H,189,220)(H,190,235)(H,191,223)(H,192,221)(H,193,222)(H,194,224)(H,195,214)(H,196,219)(H,197,218)(H,206,207)(H,208,209)(H,238,239)(H,240,241)(H,242,243)(H4,163,164,166)/t77-,78-,79-,80-,81+,89-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,109-,110-,111-,112?,113?,114?,115?,116?,117?,118?/m0/s1

Standard InChI Key:  QFFFERPCYSLUQD-IYCBLNKJSA-N

Associated Targets(non-human)

Trypsin 394 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 3423.88Molecular Weight (Monoisotopic): 3421.7670AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Heard KR, Wu W, Li Y, Zhao P, Woznica I, Lai JH, Beinborn M, Sanford DG, Dimare MT, Chiluwal AK, Peters DE, Whicher D, Sudmeier JL, Bachovchin WW..  (2013)  A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates.,  56  (21): [PMID:24044354] [10.1021/jm400423p]

Source